<DOC>
	<DOCNO>NCT01024712</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Gefitinib may stop growth tumor cell block enzymes need cell growth . Giving paclitaxel carboplatin together gefitinib may kill tumor cell . PURPOSE : This phase II trial study side effect give paclitaxel carboplatin together gefitinib see well work treat patient Stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin , Gefitinib Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine efficacy , term overall response , safety paclitaxel carboplatin combination intermittent gefitinib patient advance nonsquamous non-small cell lung cancer . Secondary - Determine disease-control rate patient treat regimen . - Determine quality life patient treat regimen . - Determine progression-free overall survival patient treat regimen . OUTLINE : Patients receive paclitaxel IV day 1 , carboplatin IV day 2 , oral gefitinib daily day 8-17 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion 4 course , patient complete response partial response may continue maintenance therapy comprise oral gefitinib daily absence disease progression unacceptable toxicity . Patients complete Functional Assessment Cancer Therapy-Lung ( FACT-L ) baseline , study treatment , completion study treatment quality-of-life study . After completion study treatment , patient follow every 2 month 2 year every 4 month thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) No squamous cell carcinoma Untreated Stage IIIB IV disease suitable surgery radiotherapy OR patient postoperative recurrence never treat chemotherapy No history smoke light smoking ( &lt; 10 pack year smoking abatement ≥ 15 year ) At least 1 measurable tumor mass ( length &gt; 1.5 cm width &gt; 1.0 cm ) No symptomatic brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count ≥ 2 x 10^9/L Platelet count ≥ 100 x 10^9/L ALT AST ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤1.5 time ULN Serum creatinine normal Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignant tumor within past year except basal cell squamous cell carcinoma skin , situ malignant cancer completely resect No history allergic reaction component drug study PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 1 month since prior investigational drug medical device No prior chemotherapy radiotherapy tumor No concurrent liposomal paclitaxel No concurrent antitumor therapy ( e.g. , radiotherapy surgical treatment ) No concurrent anticancer chemotherapy drug anticancer Chinese herb</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
</DOC>